ArticleOncology letters2016
Nanotechnology for multimodality treatment of cancer.
Article in Oncology letters, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 9 citations in OpenAlex.
- Insights into the Recent Breakthroughs in Nanotechnological Outlook of Pentacyclic Triterpenoids: An Updated Approach.Current pharmaceutical design · 2026Review
- Cancer resistance to treatment and antiresistance tools offered by multimodal multifunctional nanoparticles.Cancer nanotechnology · 2017Review
Corrections and comments
- Retraction · 2020-09-14Objections by Third Party · Plagiarism of/in Article · Taken from Dissertation/Thesis ·
- Retracted
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nanotechnology is the latest evolving field and its applications in medicine in recent decades has shown great potential. It has also given a new face to the therapeutics against cancer in recent years. The electronic databases of MEDLINE, EMBASE and PubMed were searched for recent studies, reporting the importance of nanomedicine. The concluding remarks of the above papers mostly confirmed the growing potential of nanomedicine, particularly in the field of cancer. Furthermore, nanomedicine has been observed to promote the therapeutic effect of agents by formulating them into nanocarriers. Delivery of the therapeutic agents via nanodelivery systems is dedicated to solving problems in traditional anticancer agents, including formulation in the physiological environment, their accumulation in tumor, and their adverse side effect in normal organs. The present review focused on the latest updates on nanotechnology in cancer. In conclusion, the future of any therapeutic option lies in the specific delivery of the particular drug. Additionally, this specific delivery may be achieved efficiently by nanodelivery systems and more studies should be conducted in this direction for the establishment of nanodelivery systems as gold standard delivery modules in clinical setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.